|
業務類別
|
-- |
|
業務概覽
|
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo). |
| 公司地址
| Norra Stationsgatan 93A, Stockholm, SWE, SE-112 76 |
| 電話號碼
| +46 86972000 |
| 傳真號碼
| +46 86972000 |
| 公司網頁
| https://www.sobi.com |
| 員工數量
| 1952 |
| Mr. Guido Oelkers |
Chief Executive Officer |
-- |
31/03/2026 |
| Mr. Henrik Stenqvist |
Chief Financial Officer |
-- |
31/03/2026 |
|
|
| Mr. David D. Meek |
Chairman of the Board |
31/03/2026 |
| Mr. Staffan Schuberg |
Independent Director |
31/03/2026 |
| Mr. Sven Anders Ernst Uddo Ullman |
Director |
31/03/2026 |
| Mr. Christophe Bourdon |
Independent Director |
31/03/2026 |
| Ms. Filippa Stenberg |
Director |
31/03/2026 |
| Mr. Mats Lek |
Director |
31/03/2026 |
| Ms. Katy Mazibuko |
Director |
31/03/2026 |
| Mr. Zlatko Rihter |
Director |
31/03/2026 |
| Ms. Iris Loew-Friedrich |
Independent Director |
31/03/2026 |
|
|
|
|
